Avidity Biosciences's Total Assets for the quarter that ended in Dec. 2024 was $1,563.90 Mil.
During the past 12 months, Avidity Biosciences's average Total Assets Growth Rate was 87.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 41.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 87.20% per year.
During the past 7 years, Avidity Biosciences's highest 3-Year average Total Assets Growth Rate was 191.20%. The lowest was 41.50%. And the median was 104.30%.
The historical data trend for Avidity Biosciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Avidity Biosciences's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avidity Biosciences (NAS:RNA) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Avidity Biosciences's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Avidity Biosciences Total Assets Related Terms
Thank you for viewing the detailed overview of Avidity Biosciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RNA has been successfully added to your 